Print

Legacy Healthcare Announces Breakthrough Clinical Results in Hair Re-Growth  
10/22/2012 10:56:45 AM

Lausanne, Switzerland, and Tokyo, Japan – October 22, 2012 - Legacy Healthcare, a company developing innovative products for hair and scalp disorders with a special focus on oncology supportive care, today announced clinical results of a double-blind, placebo-controlled, long-term trial of its innovative CG210™ topical treatment in patients suffering from hair loss.

The primary endpoint of the 12-month clinical study in subjects already using finasteride 1mg as a treatment for hair loss was the increase of mean diameter of hair. Participants received topical CG210™ or topical placebo in addition to the oral finasteride 1mg they were already taking. Finasteride, a synthetic type-2 5a-reductase inhibitor, has been approved by the US FDA, among others, for the treatment of male pattern baldness (MPB). As of September 27, 2012, results from 16 volunteers, who completed a 12 month cycle, were analyzed. The mean diameter of hair of subjects receiving topical CG210 increased 36.9% more than the mean diameter of hair of subjects receiving topical placebo (p<0,0001). The study was conducted in Japan.

"For the study, we enrolled men who were already using finasteride for awhile and whose hair had stopped improving,” said Dr. Akio Sato, Director of the Tokyo Memorial Clinic Hirayama, investigator of the study. “Despite the limited number of subjects, the group using topical CG210 as an add-on to finasteride showed a significant improvement in hair diameter compared to the group using topical placebo as an add-on to finasteride. Improvement in hair diameter is evidence of better hair retention and a prolonged anagen phase. For individuals who see limited improvement with finasteride, CG210 may offer a novel and very satisfactory option. Another key point is that CG210 is a botanical-based product and no adverse events have been reported in this study."

“These are exciting times for Legacy Healthcare,” said Saad Harti, President of the company. “Worldwide, there are at least 800,000 users of finasteride 1mg who might benefit from potentially improved hair pattern results thanks to the combined use of CG210. The results of this study provide an additional confirmation of the already observed clinical efficacy of our product CG210, when applied alone.”

ABOUT EXCESSIVE HAIR LOSS AND CG210™

Hair loss, e.g. induced by androgenetic alopecia, stress or chemotherapy, is characterized by excessive apoptosis which provokes more hair to enter prematurely into the catagen phase (transition phase) and fall. As a consequence, the anagen phase of hair (growing phase) becomes shorter. The successive repetition of the premature onset of the catagen phase, which is caused by massive apoptosis followed by shorter and shorter anagen phase, leads to hair miniaturization (white, invisible, thin hair), i.e. balding.

In addition to a massive apoptosis phenomenon, excessive hair loss is also associated with scalp micro- inflammation.

CG201™ has demonstrated anti hair-loss efficacy: the proportion of hair in the falling phase returned to a level considered as normal within 44 days of product application. Its hair re-growth property was demonstrated by an average number of new hairs of over 8,200 after 3 months of product application.

The above results were observed in a trial performed with the phototrichogram protocol on subjects with androgenetic alopecia using CG210 alone.

In various clinical studies, CG210 has demonstrated efficacy, safety and absence of side-effects as well as a unique and novel mechanism of action.

ABOUT LEGACY HEALTHCARE

Founded in 2005, Legacy Healthcare is an oncology supportive care and dermatology company. It develops and markets innovative products for hair & scalp disorders, with a special focus on supportive oncology treatments, in particular chemotherapy-induced alopecia.

Legacy Healthcare aims to become the first company to market a topical product for the prevention and recovery from chemotherapy-induced alopecia.

In 2012, the company has finalized the development of CG210™, a patented product for male androgenetic alopecia and female pattern hair loss. At present, the company is engaged in global partnering and out-licensing activities.

CONTACT:

Legacy Healthcare

Lorenzo Pellegrini Quarantotti

VP, Business Development & Commercial Operations

Tel.: +41 21 651 90 36

l.pellegrini_quarantotti@legacyhealthcare.ch

www.legacyhealthcare.ch

MEDIA INQUIRIES:

akampion

Dr. Ludger Wess, Ines Regina Buth

Managing Partners

Tel.: +49 40 88165964 or +49 30 2363 2768

info@akampion.com


//-->